Valeant On Stronger Ground As It Readies For Allergan Showdown
This article was originally published in The Pink Sheet Daily
The Canadian pharma reported a strong third quarter and an improved debt position as it prepares for the December meeting with Allergan shareholders that could result in an ousting of the Botox-maker’s board.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.